GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (XMAD:GRF) » Definitions » Ending Cash Position

Grifols (XMAD:GRF) Ending Cash Position : €0 Mil (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Grifols Ending Cash Position?

Grifols's Ending Cash Position for the quarter that ended in Dec. 2023 was €0 Mil.

Grifols's annual Ending Cash Position declined from Dec. 2021 (€2,676 Mil) to Dec. 2022 (€548 Mil) and declined from Dec. 2022 (€548 Mil) to Dec. 2023 (€530 Mil).

Grifols Ending Cash Position Historical Data

The historical data trend for Grifols's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Ending Cash Position Chart

Grifols Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 741.98 579.65 2,675.61 547.98 529.58

Grifols Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Grifols Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Grifols's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=547.979+-18.402
=530

Grifols's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0+0
=0

Grifols Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Grifols's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Grifols (XMAD:GRF) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (XMAD:GRF) » Definitions » Ending Cash Position
Comparable Companies
XMAD:AEDAS XMAD:NEA XMAD:BKT XMAD:ALB XMAD:NTH XMAD:AZK XMAD:BST XMAD:TRE XMAD:ACX XMAD:ELE LLY JNJ MRK ABBV LSE:AZN XSWX:ROG XSWX:NOVN PFE AMGN XPAR:SAN
Traded in Other Exchanges
GIKLY:USA GIFOF:USA GIFLF:USA GRFS:USA GRFP:Mexico GRFe:UK GRFPe:UK 0RDV:UK 0RDU:UK GRF.P:Spain OZTA:Germany
Address
Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
Website
https://www.grifols.com
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's biopharma business contributed 83% of sales in 2022. Grifols also has smaller segments including diagnostics and biosupplies. Diagnostics is roughly 10% of revenue following the Biotest acquisition.